Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Cosette Pharma
Deal Size : $430.0 million
Deal Type : Acquisition
Cosette Pharmaceuticals Acquires Mayne Pharma for Women’s Health Leadership
Details :
Product Name : Annovera
Product Type : Steroid
Upfront Cash : Undisclosed
February 20, 2025
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Cosette Pharma
Deal Size : $430.0 million
Deal Type : Acquisition
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The sNDA included minor revisions to Annovera (segesterone acetate) in vitro release testing specification that allowed for normal manufacturing variability, was approved by the FDA in August 2018 as the only long-lasting, reversible, procedure-free birt...
Product Name : Annovera
Product Type : Steroid
Upfront Cash : Inapplicable
May 20, 2022
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Rubric Capital Management
Deal Size : $15.0 million
Deal Type : Financing
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
Details : TherapeuticsMD has three growing assets whose value has been enhanced by the recent approval of both Annovera’s (segesterone acetate) supplemental NDA and lower-dose Bijuva, as well as the increasing relevance of convenient and safe contraceptive optio...
Product Name : Annovera
Product Type : Steroid
Upfront Cash : Undisclosed
January 08, 2022
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Rubric Capital Management
Deal Size : $15.0 million
Deal Type : Financing
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Population Council
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Population Council and Duchesnay Announce New International License Agreement for ANNOVERA®
Details :
Product Name : Annovera
Product Type : Steroid
Upfront Cash : Undisclosed
November 30, 2020
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Population Council
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Segesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Sponsor : Population Council
Deal Size : Undisclosed
Deal Type : Partnership
Lubrizol Expands Partnership with the Population Council
Details : This builds on a decades-long partnership between the two organizations to optimize the delivery of several vaginal products, including the Population Council’s proprietary progestin, Nestorone®, and MIV-150, and manufacturing lead formulations for to...
Product Name : Nestorone
Product Type : Steroid
Upfront Cash : Undisclosed
October 15, 2020
Lead Product(s) : Segesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Sponsor : Population Council
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : TherapeuticsMD
Deal Size : Undisclosed
Deal Type : Agreement
TherapeuticsMD and Nurx Expand Access to ANNOVERA®
Details : The agreement is aimed at expanding access to ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system), a first of its kind annual birth control ring. ANNOVERA is the first FDA-approved long-lasting birth control method that does not require...
Product Name : Annovera
Product Type : Steroid
Upfront Cash : Undisclosed
July 15, 2020
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : TherapeuticsMD
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : TherapeuticsMD
Deal Size : Undisclosed
Deal Type : Agreement
TherapeuticsMD and Afaxys Enter Into Agreement
Details : The arrangement combines Afaxys' unique capabilities serving the United States public health contraception market with TherapeuticsMD’s commitment to supply ANNOVERA to the U.S public health system.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Undisclosed
February 13, 2020
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : TherapeuticsMD
Deal Size : Undisclosed
Deal Type : Agreement